These findings were consistent with the discovery that TMUB1 promotes PD-L1 degradation, suggesting that the increase in the TMUB1 expression in cancer results in PD-L1 accumulation that drives the escape of cancer/tumor cells from antitumor immunity. Here, TMUB1 is linked to neoplasm.